Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.45
- Piotroski Score 2.00
- Grade Buy
- Symbol (AKBA)
- Company Akebia Therapeutics, Inc.
- Price $1.33
- Changes Percentage (0.76%)
- Change $0.01
- Day Low $1.31
- Day High $1.35
- Year High $2.48
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.50
- High Stock Price Target $7.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.22
- Trailing P/E Ratio -4.82
- Forward P/E Ratio -4.82
- P/E Growth -4.82
- Net Income $-51,925,000
Income Statement
Quarterly
Annual
Latest News of AKBA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets
Akebia Therapeutics saw an 11% drop in stock after reporting Q4 results, with mixed analyst opinions. Revenue forecasts show a 3% decline in 2024, with losses expected to increase....
By Yahoo! Finance | 1 month ago -
Must the show go on? Theatre's plucky motto may be out of step with our times | Arifa Akbar
This summer, stage performances faced delays, cancellations, and postponements, sparking discussions about a possible cultural shift. The industry is adapting post-Covid, prioritizing health and safet...
By The Guardian | 2 months ago -
Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
Long-term investing is advisable, but not every stock should be held forever to avoid major losses. Akebia Therapeutics (NASDAQ: AKBA) shareholders suffered an 80% drop in 5 years and 57% in the last ...
By Yahoo! Finance | 3 months ago
